Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding
Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate. This HIV-derived protein is used as an antigen target for vaccine development, and it is crucial that this target is stored in a buffer that reduces aggregation and enhances long-term stability. Learn how 2bind used Prometheus Panta to do a 96-condition buffer screen, find the optimal buffer for stability in standard and stressed conditions, and validate antibody binding to the antigen — all in one instrument.
Practical strategies for overcoming challenges in the development of AAV vectors for gene therapy
Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. W...
Mischievous membrane proteins (and how to tame them)
Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to char...
Sign up to receive the latest NanoTemper news, product updates, event announcements and more